Collagenase- and LPA₁ antagonist-functionalized lipid nanoparticles enhance mRNA delivery across fibrotic extracellular matrix barriers in a bleomycin-induced pulmonary fibrosis model

The lungs are a delicate network of air sacs designed to exchange oxygen for carbon dioxide, a process that relies on thin, flexible walls. In a condition known as idiopathic pulmonary fibrosis, this architecture is slowly destroyed and replaced by thick, rigid scar tissue. This scarring is not merely a sign of damage; it creates a dense physical barrier made of collagen, a tough protein that normally provides structure but becomes excessive and obstructive in this disease. This barrier prevents medicines from reaching the cells that need them most. While scientists have developed powerful new drugs based on messenger RNA, which can instruct cells to produce healing proteins, these drugs struggle to penetrate the scarred lung tissue. They get stuck in the thick matrix, unable to reach the activated cells driving the disease. The challenge, therefore, is not just delivering a drug to the lung, but engineering a delivery vehicle smart enough to navigate the specific, hardened landscape of a fibrotic lung.

Researchers at Chungbuk National University and their colleagues have addressed this obstacle by designing a specialized delivery system that acts as a two-part solution. They created tiny, spherical particles called lipid nanoparticles, which are commonly used to carry genetic material. However, they modified the surface of these particles with two distinct biological tools. The first tool is a form of collagenase, an enzyme that naturally breaks down collagen. The second is a molecule that acts as an antagonist, or blocker, for a specific receptor on the surface of fibroblasts, the cells responsible for building scar tissue. By attaching these two components to the same nanoparticle, the team aimed to create a vehicle that could first dissolve a path through the scar tissue and then specifically target the cells causing the scarring.

To test this concept, the researchers first synthesized the necessary components in the laboratory. They chemically linked the collagen-digesting enzyme and the receptor-blocking molecule to lipid molecules, which are the building blocks of the nanoparticles. They then used a precise mixing process to assemble these lipids into nanoparticles loaded with a type of messenger RNA that produces a red fluorescent protein, allowing the team to track where the particles went. The resulting particles were roughly the size of a virus, stable, and capable of carrying their genetic cargo. Crucially, the team verified that the enzymes attached to the surface remained active, retaining about 65 percent of their original ability to break down collagen, and that the blocking molecules could still interact with their targets.

The team then put these engineered particles to the test in a series of experiments designed to mimic the difficult environment of a fibrotic lung. When they placed the particles in a dense gel of collagen, the unmodified particles moved very slowly, trapped by the tight network. In contrast, the particles equipped with the collagen-digesting enzyme moved significantly faster, effectively carving out a path through the gel. This mobility translated directly into better penetration; when the particles were placed on top of a layer of collagen covering living cells, the enzyme-equipped particles reached the cells underneath much more effectively than the standard particles. Once inside the cells, the particles delivered their genetic message, causing the cells to produce the red fluorescent protein. The particles with the enzyme delivered about 1.7 times more of this message than the unmodified ones.

The researchers also examined the second component of their design: the receptor blocker. They found that when the particles carried this blocker, they were particularly effective at delivering their message to activated fibroblasts, the specific cells driving the disease. In experiments where fibroblasts were stimulated to become aggressive and migratory, the particles carrying the blocker successfully inhibited this movement. Furthermore, these particles delivered their genetic cargo to the activated fibroblasts about 2.4 times more effectively than particles without the blocker. This suggested that the blocker did more than just stop the cells; it also helped the particles enter them. When both tools were combined on a single particle, the benefits were cumulative, suggesting that the enzyme cleared the way while the blocker guided the particle to its target.

To see if these laboratory findings held up in a living organism, the team induced lung fibrosis in rats using a chemical that mimics the human disease. They then administered the nanoparticles to the rats' lungs using a specialized spray device. The spray produced a consistent mist of droplets, ensuring that any differences in results were due to the particles themselves and not the method of delivery. In healthy rats, both the modified and unmodified particles performed similarly, distributing evenly throughout the lungs. However, in the rats with fibrotic lungs, the difference was stark. The unmodified particles struggled to spread, remaining largely in the larger airways. The dual-functionalized particles, however, penetrated deep into the fibrotic tissue, reaching the tiny air sacs where the disease is most destructive. The amount of genetic message delivered by the modified particles was more than double that of the unmodified ones, with the most significant improvement seen in the deep alveolar regions.

This improved delivery led to tangible health benefits for the animals. The rats treated with the dual-functionalized particles showed marked improvements in their breathing mechanics. Their tidal volume, or the amount of air they could inhale with each breath, increased significantly, and their breathing patterns became slower and deeper, resembling those of healthy animals. Their blood oxygen levels also rose, indicating that the lungs were better at transferring oxygen into the bloodstream. These physiological changes were accompanied by visible improvements in the lung tissue itself. Under a microscope, the lungs of the treated rats retained much of their normal structure, with far less scarring and inflammation compared to the untreated animals. The levels of collagen and other markers of fibrosis in the lung tissue and fluid were significantly lower, and the levels of inflammatory signals were reduced.

The study suggests that the key to treating fibrotic lung diseases may lie in adapting delivery systems to the specific barriers of the disease. By combining an enzyme that clears a path through the scar tissue with a molecule that targets the cells causing the scarring, the researchers created a platform that overcomes the physical and biological hurdles of the fibrotic lung. While the current study used a reporter gene to track delivery rather than a therapeutic drug to cure the disease, the results demonstrate that this approach can successfully deliver genetic material to the right place in the right amount. The findings indicate that simply optimizing the size or stability of a drug carrier is not enough; the carrier must also be equipped to navigate the unique, hardened environment of a diseased lung. This work provides a practical framework for developing the next generation of inhaled therapies for fibrotic lung diseases, moving beyond standard delivery methods to address the specific pathological barriers that have long limited treatment success.